I found today's newletter very encouraging. Page 3, dot point #3 in under the heading 'Science Update' highlighted that the company have identified a panel of Phylomers able to inhibit MYC activity in vitro with a significant number showing equal or better activity than OmoMyc. Page 42 of the recent Technical Presentation (May 2015) highlights that the company have already identified >15 Phylomer hits which are more active than Omomyc. Note, this step represents the penultimate stage-gate to confirming whether or not the company can generate fully proprietary molecules.
They also made sure to add Perkins Institute on various slides re pilot program (refer to Technical Presentation May 2015 below) and why wouldn't they.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)